Sevelamer carbonate

Drug Profile

Sevelamer carbonate

Alternative Names: GZ 419831; Renvela

Latest Information Update: 26 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Polyamines
  • Mechanism of Action Chelating agents; Phosphate binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperphosphataemia

Most Recent Events

  • 21 Dec 2016 Sanofi plans the phase III RECOVER trial for Hyperphosphataemia in China (PO, Tablet) (NCT03001011)
  • 01 Jun 2015 Genzyme completes a phase II trial in Hyperphosphataemia (In adolescents, In children, In infants) in Poland, Lithuania, Germany, France and USA (NCT01574326)
  • 31 Mar 2014 First generic equivalent available in USA for hyperphosphataemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top